INNOGEN-B (02591) has issued an announcement disclosing that on February 4, 2026, the application for a new veterinary drug clinical trial for the company's core product, Esupaglutide α, intended for treating diabetes in companion animals, was formally accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. The initiation of the Phase I clinical trial is anticipated in the first quarter of 2026. The Board of Directors believes that the research and development of drugs for pet diabetes holds significant promise. As people increasingly demonstrate a willingness to accept and spend money to extend the lives of their pets, the Board considers this type of R&D to align with the Group's long-term business development strategy. It is expected to establish a solid foundation for the Group's future entry into the pet pharmaceuticals sector. The Group has complied with all standards and regulatory requirements related to veterinary drug R&D and registration stipulated by the Ministry of Agriculture and has successfully completed the relevant preclinical trials. Based on the results of these preclinical trials, Esupaglutide α has shown positive progress in managing pet diabetes in terms of both efficacy and safety, providing a reasonable basis for subsequent clinical trials and registration applications for this drug.